Janet Hock Inducted into Cambridge Who's Who
Janet Hock led development of Forteo, a first-in-class anabolic drug for osteoporosis

Bangor, ME, September 13, 2010 /24-7PressRelease/ -- Janet Hock, Executive Director of the Maine Institute for Human Genetics and Health, has been recognized by Cambridge Who's Who for demonstrating dedication, leadership and excellence in administrative operations.

As Executive Director of Maine Institute for Human Genetics and Health, Dr Hock specializes in exploratory clinical research in environmental oncology to improve prevention, diagnosis and treatment of cancer by studying cancer risks posed by radon, arsenic and endocrine disrupting chemicals. Maine Institute for Human Genetics and Health is a nonprofit research institute working to support innovations in individualized patient care. In the past, Dr Hock worked as lead scientist at Eli Lilly & Co to develop Forteo , a first-in-class anabolic drug for osteoporosis, and contributed to the development of Evista . At Indiana University, she founded a research and patient advocacy program in osteosarcoma. Dr Hock was Vice President Global Research at Aastrom, Inc, a biotech company with unique technology to enrich bone marrow stem cells. She oversaw clinical trials for orthopedic and dental applications.

Dr Hock received both her PhD (1974) and Bachelor of Dental Surgery (1966) from the University of London, UK. She is a member of the American Society for Bone and Mineral Research, the American Society for Clinical Oncology and the American Association for Cancer Research. She attributes her success to open-mindedness, a willingness to take risks, and skill in promoting scientific collaborations.

Press Release Contact Information:

Ellen Campbell
Cambridge Who's Who
Public Relations
498 RXR Plaza, West Tower
Uniondale, NY
USA 11556
Voice: 516-535-1515 x1266
Website: Visit Our Website